Aprotinin: An antidote for recombinant tissue-type plasminogen activator (rt-PA) active in vivo
- 1 August 1990
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 16 (2) , 507-510
- https://doi.org/10.1016/0735-1097(90)90612-s
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.Journal of Clinical Investigation, 1989
- Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model.Circulation, 1989
- The risk of reperfusion strategies in the treatment of patients with acute myocardial infarctionJournal of the American College of Cardiology, 1988
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988
- Coronary thrombolysis with tissue-type plasminogen activator (t-PA): Emerging strategiesJournal of the American College of Cardiology, 1986
- Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbitsBlood, 1986
- DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- Coronary thrombolysis in dogs with intravenously administered human pro-urokinase.Circulation, 1985
- The Thrombolysis in Myocardial Infarction (TIMI) TrialNew England Journal of Medicine, 1985
- Clinical Application of Inhibitors of FibrinolysisDrugs, 1985